Eli Lilly To Supply COVID-19 Treatment To Low-Income Countries
The announcement comes as the president is pushing the FDA to quickly approve an antibody treatment.
Eli Lilly said it's working to supply experimental COVID-19 treatments to lower income countries.
The pharmaceutical company said it's partnered with the Bill and Melinda Gates Foundation to provide the potential antibody treatment.
Eli Lilly's chairman and CEO said: "Medicines that can help reduce the impact of COVID-19 will be an important part of the solution to this pandemic and are urgently needed by people all over the world."
It's unclear how many doses of the treatment will be made available, but Eli Lilly has previously said it would have 1 million doses by the end of the year.
The announcement comes as President Trump is pushing the Food and Drug Administration to quickly approve that antibody treatment, along with one made by Regeneron for emergency use.
Why COVID vaccine outreach is still critical in 2023
Pharmacists are working to get the COVID vaccine to communities that may not have easy access to a pharmacy.By Scripps News
US proposes once-a-year COVID shots for most Americans
The FDA proposed a simplified approach for future vaccination efforts, allowing most adults and children to get a once-a-year shot to combat COVID.By Rogelio V. Solis / AP
Next COVID variant will likely be found in airplane wastewater
Dr. Cindy Friedman, with the CDC Travelers' Health Branch, says airports will likely be the first to know if a new variant comes along.By Shutterstock
Why are more married couples living apart?
The latest U.S. Census shows roughly 3.89 million American married adults are living apart.By Scripps News
Why audiences are getting their news from comedians
Getting some comedy with your news may help you remember what you’re learning.By Victoria Will / AP
How do Amazon packages get delivered so quickly?
When retailers like Amazon deliver on their speedy shipping promises, it’s good news for consumers. But it can compromise workplace safety.By Mark Lennihan / AP